teva stock: Comprehensive Guide

This guide explains teva stock (TEVA), the publicly traded equity of Teva Pharmaceutical Industries Ltd., covering listings (NYSE, TASE), ADR structure, business model, corporate history, financial...

2024-07-03 10:21:00

By ChainSync Analyst

Article rating

4.4

105 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Teva (stock)

teva stock is the ticker symbol for Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company listed on the New York Stock Exchange (NYSE) and the Tel Aviv Stock Exchange (TASE). Teva trades in the form of U.S.-listed ordinary shares/ADRs on the NYSE under the symbol TEVA and as native shares on TASE. Teva is best known for its large generics business, several specialty branded medicines and a history of major corporate actions that have materially affected the share price over time. This article explains the listings, business model, material corporate events, drivers of stock performance, financial and legal considerations, where to obtain authoritative data and practical notes on trading and custody.

Ticker and listing information

The primary U.S. ticker for Teva Pharmaceutical Industries Ltd. is TEVA. The company is dual-listed — its global equity can be traded on the New York Stock Exchange (NYSE) and the Tel Aviv Stock Exchange (TASE). On U.S. markets, Teva shares typically trade as American Depositary Receipts (ADRs) or as ordinary shares represented on the NYSE depending on the market structure at the time. Trading currency on the NYSE is U.S. dollars; trading on TASE is in Israeli shekels.

Investors who follow teva stock should be aware of basic identifiers used for market data and regulatory filings: ISIN codes, CUSIP numbers for U.S.-listed securities, and the company’s TASE listing code. For the latest identifiers and market structure details consult Teva’s investor relations materials or major finance portals.

Company overview (context for the stock)

Teva Pharmaceutical Industries Ltd. is an international pharmaceutical firm headquartered in Israel. The company’s core businesses include the development, manufacture and sale of generic medicines, a portfolio of branded specialty medicines, biosimilars and active pharmaceutical ingredients (APIs). Teva’s scale in generic medicines historically made it one of the world’s largest generic drug manufacturers by revenue and production footprint.

The investment case for teva stock is tightly linked to its business mix: generics provide high-volume, lower-margin revenue streams that are sensitive to pricing competition, while the branded specialty segment can deliver higher margins and growth if products achieve market traction. Biosimilars and APIs add diversification and operational leverage. Investors evaluate Teva on product pipeline prospects, patent expirations, generic pricing dynamics and the company’s ability to manage debt and cash flow.

History of the stock and corporate actions

Teva’s corporate and stock history includes multiple events that materially affected shareholder value. Key milestones commonly cited by investors include major acquisitions, patent expiries on legacy branded products, management changes and large restructuring programs.

Major acquisitions: Teva made several substantial acquisitions that reshaped its balance sheet and business mix. A notable example is the acquisition of Allergan’s generics business announced in 2016, a transaction that expanded Teva’s global generics footprint but also materially increased leverage.
Patent cliffs and product lifecycle events: Teva’s branded multiple sclerosis product Copaxone was historically a major revenue driver for the company. When patents on Copaxone expired and generic entrants emerged, Teva’s revenues and share price experienced pressure, illustrating how patent expirations can influence teva stock.
Restructuring and cost programs: Following large acquisitions and revenue pressures, Teva implemented global cost-reduction and restructuring programs to reduce operating expenses, optimize its product portfolio and deleverage the balance sheet.
Leadership and strategic resets: The company has undergone management changes and strategic repositioning aimed at focusing on core medicines, divesting non-core assets and prioritizing debt reduction and cash generation.

As with any large pharmaceutical firm, corporate actions such as secondary equity offerings, debt issuances, share buybacks, and asset divestitures can have important implications for shareholders and are tracked closely by markets following teva stock.

Business segments and drivers of stock performance

Teva’s stock performance typically reflects outcomes in several operating areas:

Generics

The generics segment is Teva’s largest in terms of product breadth and historically significant revenue share. Generics are volume-driven and susceptible to pricing pressure when competitors enter a market. For teva stock, unexpected downward pricing trajectories, margin compression, or loss of key procurement contracts can meaningfully affect revenue and investor sentiment.

Specialty / Branded medicines

Teva’s branded specialty portfolio contains products like Copaxone (multiple sclerosis), Ajovy (fremanezumab for migraine prevention) and Austedo (deutetrabenazine for movement disorders). Success in specialty areas depends on clinical data, regulatory approvals, payer access and competition from other branded drugs and generics. Positive regulatory decisions or strong commercial uptake of branded products can act as upside catalysts for teva stock.

Biosimilars and APIs

Biosimilars represent a growth opportunity but require investment in manufacturing and market access; approvals and market launches of biosimilars can be multi-year value drivers. APIs are part of Teva’s vertical manufacturing capability and can provide margin stability when API supply is scarce in the global market.

Key drivers investors watch

Drug approvals and regulatory decisions (FDA, EMA and other national bodies)
Patent expirations and generic competition on legacy brands
Pricing pressure in generics markets and major tender outcomes
M&A activity and asset divestitures
Debt levels, refinancing schedules and interest cost trends

Because teva stock combines exposure to low-margin generics and higher-margin specialty drugs, investors typically monitor both revenue mix and margin trends to understand the likely trajectory of earnings and cash flow.

Financial performance and key metrics

Equity investors use several financial metrics to evaluate teva stock:

Revenue and revenue growth: Trends in consolidated sales and organic revenue provide insight into product demand across generics and specialty segments.
Adjusted and GAAP EPS: Earnings per share (reported and adjusted for one-time items) show profitability and are used for valuation multiples.
Profit margins: Gross margin and operating margin reflect pricing power, manufacturing efficiency and product mix.
Cash flow and free cash flow: These metrics indicate ability to service debt, fund R&D and pay shareholder returns.
Leverage ratios: Net debt to EBITDA and interest coverage ratios are particularly important given Teva’s history of large acquisitions and resultant debt load.
Valuation multiples: Market capitalization, P/E (when positive earnings exist), EV/EBITDA and price-to-sales are commonly used to compare Teva with peers.

Stock quotes and up-to-date numeric values for market cap, P/E and other ratios change continuously. As of a recent reporting date, authoritative market portals and the company’s investor relations site provide the current figures; investors should consult those live sources before making decisions. For example: as of June 1, 2024, major finance portals reported TEVA’s current market metrics — readers should check live data feeds for the latest numbers.

Stock market data and historical performance

Historical price performance for teva stock shows periods of volatility tied to product lifecycle events, M&A activity and regulatory or legal developments. Typical market-data points investors examine include:

Price history and charts: Short-term and multi-year charts contextualize rallies and drawdowns in response to news or earnings.
52-week range: The high and low over the past 52 weeks provide a quick sense of recent volatility.
Average daily trading volume: Liquidity measures that affect trading execution and bid-ask spreads for teva stock.
Volatility: Historical and implied volatility help option market participants and risk-aware investors understand price moves.

Sources such as major finance portals and Teva’s investor relations page offer interactive charts, downloadable historical price files and market statistics. When reviewing historical performance, correlate share-price movements with corporate announcements, earnings releases and legal or regulatory news to understand causality.

Dividends, splits and corporate actions

Teva’s dividend policy, any past stock splits and buyback activity are important to income-oriented investors and those tracking changes in capitalization. Historically, Teva’s ability to pay dividends and conduct buybacks has been influenced by its leverage and cash flow priorities. Investors tracking teva stock should review recent annual reports and shareholder communications to confirm dividend status and capital allocation plans.

Share structure and major shareholders

Key ownership details that affect governance and trading dynamics for teva stock include total outstanding shares, public float, insider holdings and the largest institutional shareholders. These disclosures are available in periodic filings and the company’s investor relations materials. Institutional ownership and changes in insider holdings can influence market sentiment and voting outcomes for important corporate resolutions.

Analyst coverage and market sentiment

Sell-side analyst coverage for Teva typically includes consensus ratings (e.g., buy/hold/sell categories), price targets and thematic research on product pipelines and cost-reduction plans. Analyst catalysts that commonly move teva stock include earnings beats or misses, pipeline readouts, major regulatory decisions and material legal settlements.

Investor sentiment can also be measured with indicators such as short interest (percentage of float sold short), institutional ownership trends and media coverage. These indicators help investors gauge whether market participants are positioning for a recovery, expecting further downside, or awaiting specific catalysts.

Regulatory, legal and reputational risks

Pharmaceutical firms like Teva operate in a heavily regulated environment and are exposed to litigation risk. Material legal or regulatory issues that have impacted Teva in the past include probes and litigation related to drug pricing and commercial practices, patent disputes and other civil claims. Such matters can lead to large settlements or injunctions that materially affect cash flow and valuation.

Because legal outcomes are uncertain and frequently resolved over multi-year timelines, investor attention to ongoing litigation, settlement accruals, and regulatory findings is essential when assessing the risk profile of teva stock.

Investor relations, filings and reporting

Investors looking for authoritative, up-to-date disclosures about teva stock should rely on the following resources provided by the company and regulators:

Annual reports (Forms and local filings)
Quarterly earnings releases and presentations
SEC filings (for U.S.-listed securities) and equivalent TASE disclosures
Investor presentations, webcasts and earnings conference calls
Official press releases and material event notices

These sources provide audited financial statements, management discussion and analysis, forward-looking guidance (if provided), and risk disclosures that underpin careful analysis of teva stock.

How to trade and hold TEVA stock

Investors normally access teva stock through brokerage accounts that offer trading on U.S. exchanges (for the NYSE-listed shares/ADRs) or on Israeli markets for TASE-listed shares. Common account types include individual taxable brokerage accounts, retirement accounts where available and institutional custodial arrangements. Trading hours for the NYSE follow U.S. market hours; TASE follows Israeli market hours.

If you prefer a single platform experience for market access and custody, consider using Bitget’s services where available for equity access and custody solutions. Bitget also provides wallet solutions for digital asset custody and related services. Always confirm that your chosen provider supports the specific security listing (NYSE or TASE) and trading type (ADRs or local shares).

Note: This section is informational and not investment advice. Before trading, verify trading permissions, fees, settlement conventions and tax treatment with your broker.

Risks and considerations for investors

Major risks to consider for teva stock include:

Generics pricing pressure: Competitive tendering and multiple generic entrants can erode revenue and margins quickly.
Patent expirations and IP litigation: Loss of exclusivity on branded medicines can materially reduce revenue; conversely, successful litigation may preserve value.
Regulatory risk: Adverse FDA or other regulatory rulings can delay product launches or restrict sales.
Leverage and refinancing risk: High debt levels can strain cash flow during periods of weak revenue or rising interest rates.
Currency and geopolitical exposure: Operating globally exposes Teva to FX movements and geopolitical developments that can influence results.
Legal and reputational risk: Ongoing litigation or regulatory investigations can result in settlements, fines or reputational harm.

Investors should match exposure to these risks with portfolio objectives and conduct due diligence using primary company filings and independent research.

References

Primary sources and commonly used finance portals for authoritative information on teva stock include:

Teva corporate investor relations materials and filings (company reports and IR site). As of June 1, 2024, Teva’s investor relations site contains financial statements and stock information.
Major finance portals and market pages such as Yahoo Finance (TEVA quote), MarketWatch (TEVA), CNBC (TEVA coverage) and CNN Markets for quotes and news updates. As of June 1, 2024, these portals provide live quotes and historical charts for TEVA.
Wikipedia entry on Teva Pharmaceuticals for corporate history and broad context (useful as a secondary background source).

Note: Stock figures (price, market cap, ratios) change continuously. For current numeric values consult live sources such as those listed above or Teva’s investor relations page. Example reporting notes: "As of June 1, 2024, according to Yahoo Finance, TEVA’s market metrics are published on the TEVA quote page."

External links and where to find live data

For live quotes, up-to-date charts and recent news on teva stock, use the company’s investor relations resources and major finance portals. Additionally, broker platforms publish real-time market data and allow execution. If you plan to trade, confirm that your broker supports the NYSE listing or TASE listing depending on your preferred market.